Stock HYL HYLORIS PHARMACEUTICALS SA
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report

News Hyloris Pharmaceuticals SA

Equities

HYL

BE0974363955

Real-time Euronext Bruxelles 08:10:50 2023-09-22 am EDT Intraday chart for Hyloris Pharmaceuticals SA 5-day change 1st Jan Change
12.55 EUR +1.62% +8.19% +8.19%
Sep. 07 Transcript : Hyloris Pharmaceuticals SA, H1 2023 Earnings Call, Sep 07, 2023 CI
Sep. 06 Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

Research
Transcript : Hyloris Pharmaceuticals SA, H1 2023 Earnings Call, Sep 07, 2023
CI
Hyloris Pharmaceuticals : 2023 Half Year Result - English
PU
Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
GL
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-JUN-2023.
CI
Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)
GL
Hyloris shareholders approve all resolutions at the Annual General Meeting
GL
Hyloris shareholders approve all resolutions at the Annual General Meeting
AQ
Hyloris Pharmaceuticals Wins EUR1 Million Grant to Develop Idiopathic Rhinitis Treatment
MT
Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region
GL
Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region
AQ
Hyloris announces potential registration date for Maxigesic® IV in the US
GL
Hyloris releases Annual Report 2022, including ESG objectives
GL
Hyloris Pharmaceuticals : 2022 Audit Report KPMG - English
PU
Hyloris Pharmaceuticals : Kempen Life Sciences Conference - Amsterdam
PU
Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
GL
Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
AQ
Hyloris Partner Submits Additional Data to US FDA for Non-opioid Pain Treatment
MT
Transcript : Hyloris Pharmaceuticals SA, 2022 Earnings Call, Mar 16, 2023
CI
Hyloris reports full year results for 2022 & provides business outlook
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features

Filters

Announcement Date

Since

Until

  1. Markets
  2. Equities
  3. Stock Hyloris Pharmaceuticals SA - Euronext Bruxelles
  4. News
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer